Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study.

Takahashi R, Chiba K, Okazaki N, Era M, Yokota K, Yabe Y, Kondo C, Fukuda T, Fukushima K, Kono M, Michikoshi Y, Yamada S and 9 more

Show all authors

Iida T, Mitsumizo K, Sato S, Doi M, Watanabe K, Ota S, Shiraishi K, Yonekura A, Osaki M

Bone2 Jul 2024Cited by 3 (Europe PMC)

PMID38960296DOI10.1016/j.bone.2024.117189PepBankPUB-38960296

Publisher page PubMedAsk about this study

Jump to 16 results

Summary

PurposeThe effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).MethodsA total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate). QCT were evaluated at baseline and after 18 months of treatment.ResultsA total of 86 participants were evaluated by QCT (Spine: D-PTH: 25, W-PTH: 21, BP: 29. Hip: PTH: 22, W-PTH: 21, BP: 32. Dropout rate: 30.5 %). QCT of the vertebra showed that D-PTH, W-PTH, and BP increased total vBMD (+34.8 %, +18.2 %, +11.1 %), trabecular vBMD (+50.8 %, +20.8 %, +12.2 %), and marginal vBMD (+20.0 %, +14.0 %, +11.5 %). The increase in trabecular vBMD was greater in the D-PTH group than in the W-PTH and BP groups. QCT of the proximal femur showed that D-PTH, W-PTH, and BP increased total vBMD (+2.8 %, +3.6 %, +3.2 %) and trabecular vBMD (+7.7 %, +5.1 %, +3.4 %), while only W-PTH and BP significantly increased cortical vBMD (-0.1 %, +1.5 %, +1.6 %). Although there was no significant increase in cortical vBMD in the D-PTH group, cortical bone volume (BV) increased in all three treatment groups (+2.1 %, +3.6 %, +3.1 %).ConclusionsD-PTH had a strong effect on trabecular bone of vertebra. Although D-PTH did not increase cortical BMD of proximal femur, it increased cortical BV. W-PTH had a moderate effect on trabecular bone of vertebra, while it increased both cortical BMD and BV of proximal femur. Although BP had a limited effect on trabecular bone of vertebra compared to teriparatide, it increased both cortical BMD and BV of proximal femur.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study16

16 results from studies that gave the peptide. 16 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, vertebral trabecular vBMD increased more with daily teriparatide than bisphosphonate.
In plain wordsIn women with fragility fractures, spongy vertebral bone density increased more with daily teriparatide than bisphosphonate.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral trabecular vBMD daily versus bisphosphonate
Study
n = 54
Comparator
Bisphosphonate
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
The increase in trabecular vBMD was greater in the D-PTH group than in the W-PTH and BP groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029608
02HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, vertebral trabecular vBMD increased more with daily than weekly teriparatide.
In plain wordsIn women with fragility fractures, spongy vertebral bone density increased more with daily than weekly teriparatide.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral trabecular vBMD daily versus weekly
Study
n = 46
Comparator
Weekly teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Source sentences
Summary
The increase in trabecular vBMD was greater in the D-PTH group than in the W-PTH and BP groups.
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029607
03HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, daily teriparatide increased vertebral total vBMD by 34.8% from baseline.
In plain wordsIn women with fragility fractures, daily teriparatide increased total vertebral bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral total vBMD daily
Study
n = 25
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Total vBMD change
34.8%
daily teriparatide vertebra
Source sentences
Summary
QCT of the vertebra showed that D-PTH, W-PTH, and BP increased total vBMD (+34.8 %, +18.2 %, +11.1 %), trabecular vBMD (+50.8 %, +20.8 %, +12.2 %), and marginal vBMD (+20.0 %, +14.0 %, +11.5 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029601
04HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, daily teriparatide increased vertebral trabecular vBMD by 50.8% from baseline.
In plain wordsIn women with fragility fractures, daily teriparatide increased spongy vertebral bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral trabecular vBMD daily
Study
n = 25
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Trabecular vBMD change
50.8%
daily teriparatide vertebra
Source sentences
Summary
QCT of the vertebra showed that D-PTH, W-PTH, and BP increased total vBMD (+34.8 %, +18.2 %, +11.1 %), trabecular vBMD (+50.8 %, +20.8 %, +12.2 %), and marginal vBMD (+20.0 %, +14.0 %, +11.5 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029603
05HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, daily teriparatide increased vertebral marginal vBMD by 20.0% from baseline.
In plain wordsIn women with fragility fractures, daily teriparatide increased marginal vertebral bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral marginal vBMD daily
Study
n = 25
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Marginal vBMD change
20%
daily teriparatide vertebra
Source sentences
Summary
QCT of the vertebra showed that D-PTH, W-PTH, and BP increased total vBMD (+34.8 %, +18.2 %, +11.1 %), trabecular vBMD (+50.8 %, +20.8 %, +12.2 %), and marginal vBMD (+20.0 %, +14.0 %, +11.5 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029605
06HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, daily teriparatide increased proximal femur total vBMD by 2.8% from baseline.
In plain wordsIn women with fragility fractures, daily teriparatide increased total upper thigh bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal femur total vBMD daily
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Total vBMD change
2.8%
daily teriparatide proximal femur
Source sentences
Summary
QCT of the proximal femur showed that D-PTH, W-PTH, and BP increased total vBMD (+2.8 %, +3.6 %, +3.2 %) and trabecular vBMD (+7.7 %, +5.1 %, +3.4 %), while only W-PTH and BP significantly increased cortical vBMD (-0.1 %, +1.5 %, +1.6 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029609
07HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, daily teriparatide increased proximal femur trabecular vBMD by 7.7% from baseline.
In plain wordsIn women with fragility fractures, daily teriparatide increased spongy upper thigh bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal femur trabecular vBMD daily
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Trabecular vBMD change
7.7%
daily teriparatide proximal femur
Source sentences
Summary
QCT of the proximal femur showed that D-PTH, W-PTH, and BP increased total vBMD (+2.8 %, +3.6 %, +3.2 %) and trabecular vBMD (+7.7 %, +5.1 %, +3.4 %), while only W-PTH and BP significantly increased cortical vBMD (-0.1 %, +1.5 %, +1.6 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029611
08HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, daily teriparatide did not significantly increase proximal femur cortical vBMD from baseline.
In plain wordsIn women with fragility fractures, daily teriparatide did not significantly increase outer upper thigh bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
No significant changeProximal femur cortical vBMD daily
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Cortical vBMD change
−0.1%
daily teriparatide proximal femur
Source sentences
Summary
QCT of the proximal femur showed that D-PTH, W-PTH, and BP increased total vBMD (+2.8 %, +3.6 %, +3.2 %) and trabecular vBMD (+7.7 %, +5.1 %, +3.4 %), while only W-PTH and BP significantly increased cortical vBMD (-0.1 %, +1.5 %, +1.6 %).
4 context sentences(design, population, supporting numbers)
Summary · context
Although there was no significant increase in cortical vBMD in the D-PTH group, cortical bone volume (BV) increased in all three treatment groups (+2.1 %, +3.6 %, +3.1 %).
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029613
09HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, daily teriparatide increased proximal femur cortical bone volume by 2.1% from baseline.
In plain wordsIn women with fragility fractures, daily teriparatide increased outer upper thigh bone volume from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone volume daily
Study
n = 22
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg/day · 18 monthsAs given in this study (human).
Measurements
Cortical bone volume change
2.1%
daily teriparatide
Source sentences
Summary
Although there was no significant increase in cortical vBMD in the D-PTH group, cortical bone volume (BV) increased in all three treatment groups (+2.1 %, +3.6 %, +3.1 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029615
10HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, weekly teriparatide increased vertebral total vBMD by 18.2% from baseline.
In plain wordsIn women with fragility fractures, weekly teriparatide increased total vertebral bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral total vBMD weekly
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg/week · 18 monthsAs given in this study (human).
Measurements
Total vBMD change
18.2%
weekly teriparatide vertebra
Source sentences
Summary
QCT of the vertebra showed that D-PTH, W-PTH, and BP increased total vBMD (+34.8 %, +18.2 %, +11.1 %), trabecular vBMD (+50.8 %, +20.8 %, +12.2 %), and marginal vBMD (+20.0 %, +14.0 %, +11.5 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029602
11HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, weekly teriparatide increased vertebral trabecular vBMD by 20.8% from baseline.
In plain wordsIn women with fragility fractures, weekly teriparatide increased spongy vertebral bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral trabecular vBMD weekly
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg/week · 18 monthsAs given in this study (human).
Measurements
Trabecular vBMD change
20.8%
weekly teriparatide vertebra
Source sentences
Summary
QCT of the vertebra showed that D-PTH, W-PTH, and BP increased total vBMD (+34.8 %, +18.2 %, +11.1 %), trabecular vBMD (+50.8 %, +20.8 %, +12.2 %), and marginal vBMD (+20.0 %, +14.0 %, +11.5 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029604
12HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, weekly teriparatide increased vertebral marginal vBMD by 14.0% from baseline.
In plain wordsIn women with fragility fractures, weekly teriparatide increased marginal vertebral bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseVertebral marginal vBMD weekly
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg/week · 18 monthsAs given in this study (human).
Measurements
Marginal vBMD change
14%
weekly teriparatide vertebra
Source sentences
Summary
QCT of the vertebra showed that D-PTH, W-PTH, and BP increased total vBMD (+34.8 %, +18.2 %, +11.1 %), trabecular vBMD (+50.8 %, +20.8 %, +12.2 %), and marginal vBMD (+20.0 %, +14.0 %, +11.5 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029606
13HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, weekly teriparatide increased proximal femur total vBMD by 3.6% from baseline.
In plain wordsIn women with fragility fractures, weekly teriparatide increased total upper thigh bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal femur total vBMD weekly
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg/week · 18 monthsAs given in this study (human).
Measurements
Total vBMD change
3.6%
weekly teriparatide proximal femur
Source sentences
Summary
QCT of the proximal femur showed that D-PTH, W-PTH, and BP increased total vBMD (+2.8 %, +3.6 %, +3.2 %) and trabecular vBMD (+7.7 %, +5.1 %, +3.4 %), while only W-PTH and BP significantly increased cortical vBMD (-0.1 %, +1.5 %, +1.6 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029610
14HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, weekly teriparatide increased proximal femur trabecular vBMD by 5.1% from baseline.
In plain wordsIn women with fragility fractures, weekly teriparatide increased spongy upper thigh bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal femur trabecular vBMD weekly
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg/week · 18 monthsAs given in this study (human).
Measurements
Trabecular vBMD change
5.1%
weekly teriparatide proximal femur
Source sentences
Summary
QCT of the proximal femur showed that D-PTH, W-PTH, and BP increased total vBMD (+2.8 %, +3.6 %, +3.2 %) and trabecular vBMD (+7.7 %, +5.1 %, +3.4 %), while only W-PTH and BP significantly increased cortical vBMD (-0.1 %, +1.5 %, +1.6 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029612
15HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, weekly teriparatide significantly increased proximal femur cortical vBMD by 1.5% from baseline.
In plain wordsIn women with fragility fractures, weekly teriparatide increased outer upper thigh bone density from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseProximal femur cortical vBMD weekly
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg/week · 18 monthsAs given in this study (human).
Measurements
Cortical vBMD change
1.5%
weekly teriparatide proximal femur
Source sentences
Summary
QCT of the proximal femur showed that D-PTH, W-PTH, and BP increased total vBMD (+2.8 %, +3.6 %, +3.2 %) and trabecular vBMD (+7.7 %, +5.1 %, +3.4 %), while only W-PTH and BP significantly increased cortical vBMD (-0.1 %, +1.5 %, +1.6 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029614
16HumanRandomized controlled trialEfficacy outcome
In women with fragility fractures, weekly teriparatide increased proximal femur cortical bone volume by 3.6% from baseline.
In plain wordsIn women with fragility fractures, weekly teriparatide increased outer upper thigh bone volume from baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseCortical bone volume weekly
Study
n = 21
Comparator
Baseline
Outcome group
Bone and joint · Musculoskeletal
Studied dose
56.5 μg/week · 18 monthsAs given in this study (human).
Measurements
Cortical bone volume change
3.6%
weekly teriparatide
Source sentences
Summary
Although there was no significant increase in cortical vBMD in the D-PTH group, cortical bone volume (BV) increased in all three treatment groups (+2.1 %, +3.6 %, +3.1 %).
3 context sentences(design, population, supporting numbers)
Summary · context
The effects of daily teriparatide (D-PTH, 20 μg/day), weekly high-dose teriparatide (W-PTH, 56.5 μg/week), or bisphosphonate (BP) on the vertebra and proximal femur were investigated using quantitative computed tomography (QCT).
Summary · context
A total of 131 postmenopausal women with a history of fragility fractures were randomized to receive D-PTH, W-PTH, or bisphosphonate (oral alendronate or risedronate).
Summary · context
QCT were evaluated at baseline and after 18 months of treatment.
Show in the study text Report a problemFND-3896029616

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Effects of daily teriparatide, weekly high-dose teriparatide, or bisphosphonate on cortical and trabecular bone of vertebra and proximal femur in postmenopausal women with fragility fracture: Sub-analysis by quantitative computed tomography from the TERABIT study.

Summary

Results from this study16

Version history

Subjects

Publication types

MeSH terms

Keywords